Advanced automated insulin delivery in inpatients receiving nutritional support: a single-center, open-label, randomised controlled trial
Primary result · TIRResult — go to the resultDifference 31.7 percentage points 95% CI 18.0–45.2Authors' conclusion
The advanced AID system improves glycaemic control without increasing the risk of hypoglycaemia in inpatients receiving nutrition support, particularly in patients with acute severe pancreatitis.
Study context
- Population
- Adult inpatients receiving nutrition support who required subcutaneous insulin therapy, non-critical care surgical and medical wardsrandomised 1:1
- Participants
- 26 inpatients
- Comparison
- Advanced automated insulin delivery (AID) vs conventional subcutaneous insulin therapy
- Closed-loopn = 13
- Controln = 13reference
- Primary endpoint
- TIR: proportion of time sensor glucose within 3.9-10.0 mmol/l
- Follow-up
- Up to 20 days or until hospital discharge
Methodological detailssingle-centre, open-label
- Single-centre
- Open-label
Primary result
TIR
Difference
31.7 percentage points
95% CI 18.0–45.2
P < 0.001
By group
Closed-loopvs Control
difference 31.7 percentage points (95% CI 18.0–45.2); P < 0.001
As reported in the abstract
Further findings
Time below target range (< 3.9 mmol/l)
- Did not differ between groups
Safety
Events
| Outcome | Closed-loop | Control |
|---|---|---|
| Serious adverse events | 0 | 0 |
| Severe hypoglycaemia or hyperglycaemia with ketonaemia | 0 | 0 |
Original publication
Advanced automated insulin delivery in inpatients receiving nutritional support: a single-center, open-label, randomised controlled trial. Diabetes Metab. Published 3 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →